戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 e, convenient and sustained formulations for topical therapy.
2 py, radiotherapy, intralesional therapy, and topical therapy.
3 oted no pain or discomfort attributed to the topical therapy.
4 ons did not offer any beneficial effect over topical therapy.
5 ty to deploy corrective, mechanism-targeted, topical therapy.
6 re sustained ocular hypertension and require topical therapy.
7 nts of the responsibility for self-dosing of topical therapy.
8 indicating maximal disease) receiving stable topical therapy.
9 ormed calcipotriol cream, a current standard topical therapy.
10 ocular pressure was 26 mmHg, despite maximal topical therapy.
11 th mild to moderate disease receiving stable topical therapy.
12 the pathophysiology of acne and pre-existing topical therapies.
13  contributes to individuality in response to topical therapies.
14 roximately 10% of patients do not respond to topical therapies.
15 riasis that was not adequately controlled by topical therapies.
16 20 nodules and severe itch uncontrolled with topical therapies.
17 was created in C57BL/6 mice, without or with topical therapy, 1% methylprednisolone, 0.025% doxycycli
18 mprovement in PASI score of 33%, with use of topical therapy (60%), biological therapy (66%, mostly a
19                 Of the patients with primary topical therapy, 62% were treated with interferon (IFN)
20                                              Topical therapy achieved high closure rates in secondary
21 sesses transcorneal penetration of candidate topical therapies, allowing rates of trans-corneal penet
22 atients with sterile inflammation undergoing topical therapy alone vs invasive procedures (vitreous b
23 ve intrastromal injection of voriconazole or topical therapy alone.
24 nce of remission was possible with proactive topical therapy alone.
25                              Enhancements in topical therapy and phototherapy have also increased the
26 uidance, and the combined use of appropriate topical therapy and short-term oral JAK inhibitors durin
27 r, standard chemotherapy, radiation therapy, topical therapies, and interferon-alpha remain the mains
28                                              Topical therapy avoids the morbidity of excisional surge
29 erium isolated from healthy human skin, as a topical therapy for AD.
30          This highlights the significance of topical therapy for atopic dermatitis and the importance
31  these parameters could lead to new forms of topical therapy for dermatoses (e.g., psoriasis, atopic
32                 One aphakic patient required topical therapy for glaucoma.
33         AGN-190584 is a safe and efficacious topical therapy for presbyopia through 30 days.
34 arations are being examined in the clinic as topical therapy for psoriasis.
35                  Anthralin is a widely used, topical therapy for psoriasis.
36 ty for developing SMAD7-based biologics as a topical therapy for skin inflammatory disorders.
37  suggest the potential use of CBD as a novel topical therapy for the treatment of glaucoma.
38                                     However, topical therapy forms the basis of the treatment for ato
39                                   No oral or topical therapy has been shown to be efficacious when ad
40 ients with significant nail disease for whom topical therapy has failed, treatment with adalimumab, e
41 te-to-severe atopic dermatitis on background topical therapy in inducing early reductions of itch and
42 he human nail remains a difficult challenge; topical therapy, in particular, is limited by very poor
43                                              Topical therapies including benzoyl peroxide, retinoids,
44                                              Topical therapy including tretinoins, hydroxy acids, ble
45  cutaneous leishmaniasis, treatment involves topical therapies, including cryotherapy, thermotherapy
46  the treatment for atopic dermatitis, and if topical therapy is appropriately established with long-t
47                   Among these products, AgNP topical therapy is proposed for treating patients with u
48                       A subgroup analysis of topical therapies, limited to saline irrigation and nasa
49                                Anti-androgen topical therapies may be a promising future area of rese
50  atopic dermatitis that is uncontrolled with topical therapies might have suboptimal efficacy and saf
51 rabeculoplasty (SLT, n = 8 eyes), initiating topical therapy (n = 8 eyes), or adding a second medicat
52 ular system, as a promising strategy for the topical therapy of arthritis.
53 sk of glaucoma progression, moving away from topical therapy offers the potential for better long-ter
54 ive percent of relapses were controlled with topical therapy only.
55  months or to control nonsystemic treatment (topical therapies or phototherapy).
56 e accessibility of HPV-associated lesions to topical therapy, our results suggest that large interfer
57                Rescue therapy use, including topical therapy, phototherapy, and systemic therapy, was
58               For milder forms of psoriasis, topical therapies, primarily corticosteroids, remain the
59                                              Topical therapies reduce systemic exposure, but can be d
60                                              Topical therapies remain the cornerstone for treating mi
61                            For mild disease, topical therapies remain the first-line treatment, inclu
62  than blood as a source of energy, our novel topical therapy significantly accelerated wound healing
63                                              Topical therapies such as retinoids (eg, tretinoin, adap
64 nts were excluded who were receiving chronic topical therapy, such as glaucoma medications, or had a
65 alized disease can be effectively managed by topical therapy, surgery or radiotherapy.
66                                    Among the topical therapies, tapinarof (aryl hydrocarbon receptor)
67 e atopic dermatitis that does not respond to topical therapy, temporary systemic administration of mo
68                  In support of this concept, topical therapies that improve epidermal function can mi
69 osine-derived fibers offer the potential for topical therapies that require ultrafast or fast dose-co
70 ave important clinical implications, because topical therapies that target IFN-gamma signaling in ker
71 nvolvement leads to the inappropriate use of topical therapy, the standard of care for causes of cica
72 patients with active disease despite optimum topical therapy to treatment with azathioprine (n=42) or
73  for more severe disease; for anal fissures, topical therapy using a calcium channel antagonist or ni
74                                              Topical therapy was attempted in 9 eyes (8 patients).
75                                              Topical therapy was used in 82.7%, and 34.2% received lo
76 or differential effects, intra-articular and topical therapies were superior to oral treatments in re
77  22, 2019, for secondary FTMHs who underwent topical therapy were included.
78 re plaque psoriasis who had not responded to topical therapy were randomly assigned with an interacti
79                                              Topical therapies with improved antiviral efficacy, bioa
80 nts, virustatic agents, or immune-modulating topical therapies with placebo or an active control.
81 ociated with uveitis was seen in response to topical therapy with difluprednate in 78% of eyes with C
82                                              Topical therapy with moderate doses of triamcinolone ace
83 idergic innervation and positive response to topical therapy with SP suggest that SP plays a critical
84        Here using mouse models, we show that topical therapy with tacrolimus, an anti-T-cell immunosu
85 ipants received any antibiotics (systemic or topical therapy) within 1 month before the study.